Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
F 25.64 -3.93% -1.05
GLPG closed down 3.93 percent on Wednesday, November 20, 2024, on 2.54 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness -3.93%
Oversold Stochastic Weakness -3.93%
Pocket Pivot Bullish Swing Setup -5.04%
Inside Day Range Contraction -5.04%
Gapped Up Strength -5.04%
MACD Bearish Signal Line Cross Bearish -4.33%
MACD Bullish Signal Line Cross Bullish -8.10%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Fell Below Lower Bollinger Band about 17 hours ago
60 Minute Opening Range Breakout about 20 hours ago
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Galapagos NV Description

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Acid Autoimmune Disease Clinical Development Inflammation Monoclonal Antibodies Inflammatory Diseases Psoriasis Rheumatoid Arthritis Inflammatory Bowel Disease Ulcerative Colitis Osteoarthritis Ulcer Cystic Fibrosis Abdominal Pain Colitis Arthritis Fatty Acids Janus Kinase Treatment Of Inflammation Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases

Is GLPG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 42.455
52 Week Low 24.16
Average Volume 203,656
200-Day Moving Average 29.36
50-Day Moving Average 28.76
20-Day Moving Average 27.47
10-Day Moving Average 27.14
Average True Range 0.80
RSI (14) 34.21
ADX 16.67
+DI 17.54
-DI 32.70
Chandelier Exit (Long, 3 ATRs) 28.61
Chandelier Exit (Short, 3 ATRs) 27.90
Upper Bollinger Bands 29.38
Lower Bollinger Band 25.57
Percent B (%b) 0.02
BandWidth 13.85
MACD Line -0.62
MACD Signal Line -0.51
MACD Histogram -0.1117
Fundamentals Value
Market Cap 1.69 Billion
Num Shares 65.9 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -10.17
Price-to-Sales 4.79
Price-to-Book 0.93
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.87
Resistance 3 (R3) 26.96 26.63 26.67
Resistance 2 (R2) 26.63 26.32 26.59 26.60
Resistance 1 (R1) 26.14 26.13 25.98 26.05 26.53
Pivot Point 25.81 25.81 25.73 25.77 25.81
Support 1 (S1) 25.32 25.50 25.16 25.23 24.75
Support 2 (S2) 24.99 25.31 24.95 24.68
Support 3 (S3) 24.50 24.99 24.62
Support 4 (S4) 24.41